Inclisiran label adds adults and adolescents aged 12 and older

The U.S. Food and Drug Administration revised the LEQVIO (inclisiran) label effective 19 August 2026. The updated indication states that LEQVIO is used as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol, or LDL-C, in adults with hypercholesterolemia and in pediatric patients aged 12 years and older with heterozy.

The supplied label summary identifies this event as an update to the product’s indications and usage. It does not provide clinical-trial results, dosing information, safety findings, comparative effectiveness data, or a new mechanism description.

Background

LEQVIO is the brand name associated with inclisiran and inclisiran sodium. The revised label describes its use alongside diet and exercise for LDL-C reduction. The indication covers adults with hypercholesterolemia and extends to pediatric patients aged 12 years and older with the condition described in the supplied label summary as “heterozy.”

The available data do not specify whether the revision introduced a new approval, changed an existing age range in detail, or modified other parts of the prescribing information. They identify the event as an FDA label revision affecting indications and usage.

What changed

• LEQVIO’s stated use is as an adjunct to diet and exercise.
• The treatment objective identified in the label summary is reduction of LDL-C.
• The adult population is described as adults with hypercholesterolemia.
• The pediatric population is described as patients aged 12 years and older with heterozy.

What this means

The revised indication provides label language for LDL-C reduction in adults with hypercholesterolemia and in pediatric patients aged 12 years and older within the population specified by the FDA label summary. Clinicians and researchers should consult the complete prescribing information for the precise wording of the pediatric condition and for any additional requirements or limitations.

Because the supplied event record contains no outcome measurements or trial analysis, it does not establish a treatment effect size, superiority over a comparator, or a new safety conclusion. It also does not provide details about how the revised indication should be applied beyond the statement that LEQVIO is used with diet and exercise.

Source

Source: FDA, DailyMed drug-label document for LEQVIO, effective 19 August 2026. The authoritative source is hosted at dailymed.nlm.nih.gov. The document’s set identifier is 6fc0afca-4513-4c35-b594-6544aee29a44.